Hanmi & Organon maintain ₩70 billion worth contract

Co-sale with existing MSD

Continued copromotion such as Propecia, Proscar, and Fosamax

Hanmi has maintained a copromotion contract with Organon, which is separated from MSD.

 

According to the Financial Supervisory Service on the 18th, Hanmi signed a domestic copromotion contract with Organon in the second quarter.

 

The contract is due at the end of this year.

 

The items include hair loss treatment Propecia, prostate hypertrophy treatment Proscar, and osteoporosis treatment Fosamax.

 

The total amount of prescriptions last year amounted to ₩67.7 billion.

 

Propsia's prescription amount is ₩41.3 billion, Prosca's prescription amount is ₩14.3 billion, and Fosamax's prescription amount is ₩12.2 billion.

 

Hanmi had already signed a contract with MSD to promote its products.

 

However, the contract was changed as Oganon spun off the MSD earlier this year.

 

In the end, Hanmi and Organon signed a new contract with the same contents.

 

Hanmi has signed contracts with MSD and Organon for more than 10 years.

 

The renewal of the contract is also due to the contract made in 2014.

 

At that time, the two companies drew attention by signing a two-way contract to mutually promote products from each company, rather than a one-way contract for domestic companies to promote items from multinational companies.

 

Hanmi has decided to jointly sell MSD's Propecia, Proscar, Fosamax, Andriol, Livial, Cosopt-S, Emend, Invanz, and Ezetrol.

 

MSD has decided to co-promote Hanmi (such as PalPal and Tamsulosin).

 

Earlier in 2009, MSD signed an overseas export contract with Amosartan, a hypertension combination drug of Hanmi.

 

It was the first time a multinational pharmaceutical company sold a drug developed by a domestic company.

 

It is currently sold in more than 50 countries under the name Cozaar XQ.

 

Last year, MSD signed a license agreement with Hanmi to develop, manufacture, and commercialize dual agonist for non-alcoholic fatty hepatitis (NASH) treatments, which was canceled due to the return of Janssen's rights.

 

In March this year, Hanmi's hyperlipidemia combination drug Rosuzet was released in Mexico under the name of NAXZALLA, and Organon is in charge of local marketing.

 

Hanmi signed an export contract with MSD in 2017 to 23 countries, but the contract was recently changed following the establishment of Organon.